A Novel Way to Fight Drug-Resistant Bacteria
Host-directed therapy can boost a patient’s immune response instead of relying only on antibiotics via Scientific American
many other antibacterial drugs (both natural and semisynthetic) have been introduced; however, within a few years of their clinical use, pathogens resistant to those drugs emerged as well.
The recent emergence of a carbapenem-resistant pathogen is the most worrying of all, because this drug is the last known line of defense against microbes that are resistant to multiple antibiotics. This is a growing concern worldwide. In the United States alone, according to the Centers for Disease Control and Prevention (CDC), drug-resistant bacterial infections kill more than 23,000 people every year and cost the country annually at least $20 billion in addition to direct healthcare expenses.
Unfortunately, there is a severe shortage of new antibacterial drugs in the development pipeline, and most of the those that are currently in use are modifications of existing classes of drugs. This poses great challenges to physicians treating severe infections, and has led to the fear of the arrival of a post-antibiotic era.
But recent advancement in scientists’ understanding of host-pathogen relationship has given scientists insights into an alternative approach called host-directed therapy (HDT), a suite of treatments whose goal is to enhance the host’s own immune response rather than relying exclusively on antibacterial drugs.